Selected article for: "high throughput and immune status"

Author: Antonishyn, Nick A.; Levett, Paul N.
Title: Molecular Diagnostic Assays for Detection of Viral Respiratory Pathogens in Institutional Outbreaks
  • Cord-id: qjab20j6
  • Document date: 2012_8_16
  • ID: qjab20j6
    Snippet: Outbreaks of viral respiratory disease in institutions may be associated with high morbidity and mortality, depending upon the viral etiology and the age and immune status of the affected patients. Control of outbreaks may include isolation and/or cohorting, and prohylaxis or treatment with specific antiviral agents may be indicated, all dependent upon the specific cause of the outbreak. Conventional methods of viral diagnosis detect only a limited number of the viruses that are known to cause o
    Document: Outbreaks of viral respiratory disease in institutions may be associated with high morbidity and mortality, depending upon the viral etiology and the age and immune status of the affected patients. Control of outbreaks may include isolation and/or cohorting, and prohylaxis or treatment with specific antiviral agents may be indicated, all dependent upon the specific cause of the outbreak. Conventional methods of viral diagnosis detect only a limited number of the viruses that are known to cause outbreaks. The availability of sensitive and specific molecular assays has facilitated rapid diagnosis of a wider range of viruses from respiratory outbreaks. Molecular methods have distinct advantages over conventional methods, including the ability to rapidly develop assays for emerging viruses and new variants of existing viruses. In addition, molecular testing allows rapid detection of resistance to antiviral agents or mutations leading to increased virulence. However, high-throughput molecular testing requires batch processes that may compromise the ability to respond quickly to urgent testing demands.

    Search related documents:
    Co phrase search for related documents
    • acid amplification technology and acute sars cov respiratory syndrome coronavirus: 1
    • acid amplification technology and low number: 1
    • acid amplification technology and low sensitivity: 1
    • acid amplification technology and low specificity: 1, 2
    • acid sequence and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45
    • acid sequence and low number: 1, 2, 3
    • acid sequence and low sensitivity: 1
    • acid sequence and low specificity: 1
    • acute sars cov respiratory syndrome coronavirus and additional cost: 1, 2, 3, 4, 5
    • acute sars cov respiratory syndrome coronavirus and adenovirus enterovirus: 1
    • acute sars cov respiratory syndrome coronavirus and long term care facility: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute sars cov respiratory syndrome coronavirus and low number: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
    • acute sars cov respiratory syndrome coronavirus and low sensitivity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51
    • acute sars cov respiratory syndrome coronavirus and low specificity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
    • acute sars cov respiratory syndrome coronavirus and luminex xmap: 1
    • additional cost and low number: 1